Overview of Remicade

Property	Description
Active Ingredient	Infliximab
Form	Lyophilized powder for concentrate
Pharmacological Class	Disease-Modifying Anti-Rheumatic Drug (DMARD), Biologic
General Purpose	To achieve sustained downregulation of inflammation
Origin	Biological (Chimeric Monoclonal Antibody)

What Type of Medicine is Remicade?

Remicade is a prescription-only medicine and the originator biologic containing the active ingredient Infliximab, which is recognized globally as a highly effective biological response modifier. This substance belongs to the pharmacological class of Disease-Modifying Anti-Rheumatic Drugs (DMARDs). Infliximab is further defined as a chimeric monoclonal antibody (mAb), confirming its unique, biological origin as a complex protein engineered to specifically target components of the human immune system. Its specific structure, partially derived from mouse proteins, differentiates it from fully humanized biologics.

Composition and Physical Form of Infliximab

The foundation of Remicade is Infliximab, a single-active-ingredient product designed to act as a cytokine blocker. The medicine is supplied as a sterile, lyophilized powder for concentrate in vials, which requires reconstitution into an aqueous solution for use. This particular form is prepared exclusively for a specific route of administration, which is by controlled intravenous infusion. This specific formulation and mandatory delivery method are clinically recognized as crucial for managing serious autoimmune conditions, ensuring the therapeutic efficacy of the complex protein structure.

What is the General Purpose of This Biologic Therapy?

The general purpose of this therapy is to achieve the sustained downregulation of inflammation by interfering with a key biological messenger. Infliximab acts as a selective immunosuppressant by binding to and neutralizing tumor necrosis factor alpha (TNF-alpha), a protein that drives chronic inflammation. This mechanism is pharmacologically confirmed to stabilize the underlying disease activity rather than just managing symptoms. By blocking this primary inflammatory signal, Remicade functions as maintenance therapy to help control the excessive, destructive immune activity present in inflammatory conditions.

Regulatory References

What side effects are possible with Remicade?

Possible Side Effects and Safety Information

Official regulatory documents classify the possible adverse reactions associated with infliximab based on the frequency observed in clinical studies and their clinical significance. The safety profile is structured around defined categories of risks, ensuring clear communication of known potential effects.

Frequency-Classified Adverse Reactions

Adverse reactions that are reported to be very common (occurring in 10% or more of patients) according to official labeling include infections (such as upper respiratory tract infection, pharyngitis, and sinusitis), infusion-related reactions, headache, and abdominal pain. Reactions classified as common (occurring in 1% to less than 10% of patients) include nausea, diarrhea, dyspepsia, rash, fatigue, fever, chest pain, and dyspnea (shortness of breath).

Serious Safety Considerations

The regulatory safety profile highlights the risk of Serious Infections, which includes the reactivation of latent Tuberculosis (TB) and Hepatitis B Virus (HBV), as well as the potential for invasive fungal infections. The official label also documents an increased risk of certain Malignancies, particularly lymphoma, including Hepatosplenic T-cell Lymphoma (HSTCL). Cases of severe Hepatotoxicity and new onset or worsening Heart Failure are also noted as serious adverse reactions.

Safety Patterns and Constraints

Adverse events are grouped by System-Organ-Classes (SOC) and cover potential effects on the Nervous System, Blood and Lymphatic System, and Hepatobiliary system. The label notes specific time-related patterns, such as Infusion Reactions which may occur during or within 24 hours of administration, and Delayed Hypersensitivity Reactions (serum sickness-like) which typically occur 3 to 12 days later. Official constraints state that the medicine is contraindicated in individuals with active severe infection and moderate-to-severe heart failure (NYHA Class III/IV). Safety considerations for pediatric patients include a documented increased incidence of malignancy.

Overdose and Emergency Response

Overdose and when to seek help

The official regulatory profile for Remicade (Infliximab) overdose is based on observation and procedural safety measures. This guidance reflects clinical trial findings and the nature of the intravenously administered biologic.

Documented Overdose Findings

Property	Official Regulatory Statement
Documented Manifestations	Clinical studies reported no direct toxic effect or dose-limiting toxicity when single doses of Infliximab up to 20 mg/kg were administered.
Physiological Systems Affected	No specific physiological systems are listed as being directly affected by overdose. The regulatory guidance requires close monitoring for any developing adverse reactions or effects.
Antidote Information	No specific antidote is known or documented for Infliximab overdosage in the official prescribing information.

Emergency Response and Required Actions

The regulatory guidance focuses on immediate patient monitoring and supportive care. In the event of an overdosage, the patient must be monitored for any signs or symptoms of adverse reactions or effects. Regulatory bodies mandate that appropriate symptomatic treatment be instituted immediately by the supervising healthcare professional. These actions constitute the required response to overexposure, which is necessary due to the lack of a known specific antidote. No specific population-related overdose concerns are addressed in the official labeling.

Therapeutic Uses of Remicade

Remicade (infliximab) is one therapeutic option used in managing several chronic inflammatory conditions. It is relevant for managing symptoms related to inflammatory or irritative states, thereby offering supportive symptomatic management in conditions marked by increased physiological stress.

Remicade is commonly used across conditions characterized by periods of heightened symptoms in both the digestive and musculoskeletal systems. The indications include: moderately to severely active Crohn's disease and Ulcerative Colitis (in adults and children), Rheumatoid Arthritis (combined with methotrexate), Ankylosing Spondylitis, Psoriatic Arthritis, and Plaque Psoriasis.

For patients, this therapy contributes to easing the overall symptom burden and provides supportive relief when symptoms interfere with routine activities. It is often used during phases when symptoms become more noticeable. This therapy is commonly used to help with supportive relief and may help patients cope more steadily with symptom fluctuations.

Quick Fact: Focus on Symptoms related to physical discomfort

In these contexts, Remicade may assist with managing symptoms of increased neurological or muscular activity and helps maintain a sense of stability when symptoms are more noticeable, supporting general well-being during symptomatic phases.

Eligibility and Restrictions for Use

The eligibility for Remicade (infliximab) is strictly defined by government regulatory documents and is based on patient population, clinical status, and age.

Contraindications and Restrictions

Remicade must not be used (is contraindicated) in patients with a prior severe hypersensitivity reaction to infliximab or any of its components, or in those with moderate to severe heart failure (NYHA Class III/IV). Use is also prohibited in patients with an active severe infection, including active tuberculosis.

Eligibility Status	Patient Population / Condition
Eligible	Adults (≥18) for all approved uses.
Eligible (Conditional)	Patients with latent TB (requires pre-treatment); HBV carriers (require monitoring); Mild heart failure (requires close monitoring).
Restricted Pediatric Use	Children aged 6 years and older (only for Crohn's Disease and Ulcerative Colitis).
Not Established	Patients with severe hepatic or renal impairment (no dose recommendations available).
Not Recommended	Pregnant women and breastfeeding mothers.

Official labeling states that the safety and effectiveness of Remicade have not been established in children under six years of age, or for pediatric use in conditions other than Crohn's Disease and Ulcerative Colitis.

What should I know about interactions with other medicines?

Interactions with other medicines and products

This section outlines the officially documented interaction patterns for Remicade (infliximab), based strictly on regulatory prescribing information.

Contraindicated and Not Recommended Combinations

The co-administration of Remicade is prohibited with Live Vaccines and Therapeutic Infectious Agents, such as BCG for bladder instillation, due to the substantial risk of clinical infection. Co-administration is not recommended or should be avoided with other biologic DMARDs, including other TNF blockers, Anakinra, Abatacept, and Tocilizumab, because these combinations increase the incidence of serious infections without proven additional clinical benefit.

Exposure and Metabolic Interactions

Concomitant use with Methotrexate (MTX) or other Immunomodulators (like Azathioprine) is associated with an increase in Remicade plasma concentrations. Regulatory documents note that initiating or stopping Remicade may alter the formation of CYP450 enzymes, potentially affecting the plasma levels of co-administered drugs that are CYP450 substrates with a narrow therapeutic index.

Administration and Timing Constraints

Remicade must not be infused concomitantly in the same intravenous line with any other medicinal product. A specific timing restriction applies to the pediatric population: live vaccines must be delayed for at least six months in infants who were exposed to Remicade in utero due to the potential for placental transfer.

Mechanism of Action

Remicade (Infliximab) functions by executing a highly specific, dual-action mechanism targeting the core drivers of chronic inflammation.

1. Neutralizing Tumor Necrosis Factor alpha (TNF-alpha)

This domain centers on Infliximab's direct binding and neutralization of the pro-inflammatory protein TNF-alpha—both its circulating (soluble) and cell-surface (transmembrane) forms. By acting as a molecular antagonist, the drug blocks TNF-alpha from engaging its receptors, thereby inhibiting the early molecular steps that escalate the inflammatory cascade and reducing the synthesis of downstream mediators like IL-6. This core action initiates a cascade resulting in the downregulation of systemic inflammatory mediators.

2. Promoting Targeted Elimination of Activated Immune Cells

Beyond simple neutralization, the mechanism includes an active immunosuppressive component. By binding to transmembrane TNF-alpha on highly activated immune cells (like T-cells and macrophages), Infliximab triggers apoptosis (programmed cell death) and mediates cell lysis. This targeted elimination reduces the physical accumulation of destructive leukocytes in inflamed tissues, which modulates the processes leading to cellular and tissue destruction driven by chronic immune activity.

Dosage and Administration Information

Official Administration Guidelines

Remicade is a lyophilized powder supplied in single-use 100 mg vials and must only be administered by Intravenous (IV) Infusion. Its use is based on a weight-based dose calculated in mg/kg and follows a rigid, cyclic treatment schedule. The administration must occur under the supervision of a qualified healthcare professional.

Standard Dosing Regimens and Schedule

Treatment is divided into a three-dose Induction Phase (Weeks 0, 2, and 6) followed by a Maintenance Phase.

Indication (Adult & Pediatric ge 6 years)	Induction Dose	Maintenance Schedule	Co-therapy Requirement
Rheumatoid Arthritis (RA)	3 mg/kg	Every 8 weeks	Must be given with methotrexate
Crohn's Disease, Ulcerative Colitis, etc.	5 mg/kg	Typically Every 8 weeks	Not required for all indications

For patients with an inadequate response, established protocols allow dose increases up to 10 mg/kg or shortening the maintenance interval to as often as every 4 weeks for certain adult indications.

Procedural and Administration Conditions

Preparation: The powder must first be reconstituted with Sterile Water for Injection, gently swirled, and then further diluted in 250 mL of 0.9% Sodium Chloride Injection, USP. The resulting infusion must be administered using an in-line, low-protein-binding filter.

Infusion Time: The medication must be administered slowly, requiring an infusion duration of not less than 2 hours (minimum 120 minutes). The prepared solution must be administered within 3 hours of reconstitution and dilution. If a maintenance infusion is missed, established guidance recommends administering the dose immediately and then resuming the schedule every 8 weeks from the date of the received dose.

Population: No specific dosage adjustment is required for older adults or those with renal or hepatic impairment.

Recent Clinical Evidence

Remicade: Recent Clinical Evidence

Remicade (infliximab) is an established monoclonal antibody that targets tumor necrosis factor-alpha (TNF-alpha), a key protein involved in systemic inflammation. It is indicated for treating several chronic inflammatory conditions across gastroenterology, rheumatology, and dermatology.

Established Indications and Foundational Studies

Clinical trials have supported the use of Remicade for reducing signs and symptoms and maintaining clinical response and remission across multiple patient populations. Key approved indications, supported by substantial evidence from randomized controlled trials (RCTs), include:

Gastroenterology: Crohn's disease (CD) in adults and pediatrics, including fistulizing CD; Ulcerative Colitis (UC) in adults and pediatrics.
Rheumatology: Rheumatoid Arthritis (RA) (used in combination with methotrexate), Ankylosing Spondylitis (AS), and Psoriatic Arthritis (PsA).
Dermatology: Chronic severe Plaque Psoriasis.

Ongoing Research and Modern Therapeutic Approaches

Recent research focuses on optimizing patient outcomes and expanding treatment flexibility, particularly concerning biosimilars of infliximab. Studies published in 2024 and ongoing trials are investigating:

Subcutaneous (SC) Formulations: Trials have compared the efficacy and safety of newer subcutaneous infliximab biosimilars (CT-P13 SC) against placebo for maintenance therapy in patients with moderate-to-severe CD and UC who initially responded to intravenous induction. Outcomes often include higher rates of clinical remission and mucosal healing in the subcutaneous groups compared to placebo.
Monotherapy vs. Combination Therapy: Research continues to explore whether monotherapy with infliximab in inflammatory bowel disease is associated with comparable outcomes to combination therapy (infliximab plus an immunosuppressant), suggesting potential flexibility in treatment strategies.
Precision Dosing: Ongoing clinical trials are evaluating whether individualized, concentration-guided dosing of infliximab (precision dosing) may be associated with improved deep remission rates compared to conventional, weight-based dosing, particularly in pediatric and young adult patients with CD.

Frequently Asked Questions (FAQ)

Common questions about Remicade (FAQ)

Q: Is Remicade considered a type of chemotherapy?

A: Remicade is officially described as a biologic medicine and a Tumor Necrosis Factor-alpha (TNF-alpha) blocker. It is categorized as a selective immunosuppressant because it targets a specific protein that drives inflammation. This mechanism of action is distinct from that of traditional chemotherapy medicines.

Q: Does Remicade affect your immune system permanently?

A: The official product label describes the active ingredient, infliximab, as having a measured median terminal half-life ranging from 7.7 to 9.5 days. This measurement indicates the rate at which the substance is cleared from circulation.

Q: Is it possible to take Remicade while also taking methotrexate?

A: Official prescribing information confirms that for the treatment of Rheumatoid Arthritis, Remicade is specifically indicated for use in combination with methotrexate. Co-administration with methotrexate or other immunomodulators is documented in official texts for other inflammatory conditions as well.

Q: Does Remicade affect how vaccines work in the body?

A: Remicade is contraindicated with live vaccines and therapeutic infectious agents due to the substantial risk of clinical infection. The regulatory label does not provide specific details on the efficacy of non-live (inactivated) vaccines during therapy.

Q: Is it possible for Remicade to stop working after a while?

A: Regulatory documents note that the treatment regimen can be adjusted if a patient experiences an inadequate therapeutic response to the standard dose. For certain adult indications, this may involve adjusting the dose or shortening the time interval between infusions.

Q: Can Remicade be used to treat Lupus?

A: The official indications listed by regulatory authorities do not include Lupus (Systemic Lupus Erythematosus). The medicine is approved for specific chronic conditions like Crohn's Disease, Ulcerative Colitis, Rheumatoid Arthritis, Ankylosing Spondylitis, Psoriatic Arthritis, and Plaque Psoriasis.

Q: Does Remicade stay in your body for a long time?

A: The active ingredient in Remicade, infliximab, has a measured median terminal half-life ranging from 7.7 to 9.5 days. This measurement describes the rate at which the substance is cleared from circulation.

Q: Can Remicade be used for conditions other than Crohn's or rheumatoid arthritis?

A: Yes, Remicade is officially indicated for treating several other conditions besides Crohn's Disease and Rheumatoid Arthritis. These approved uses include Ulcerative Colitis, Ankylosing Spondylitis, Psoriatic Arthritis, and Plaque Psoriasis.

Q: Is Remicade a cure for inflammatory conditions?

A: Official patient information explicitly states that Remicade is a medicine used to manage and help control chronic conditions, and it will not cure rheumatoid arthritis or Crohn's disease.

Q: Is Remicade the first treatment option for IBD?

A: For Crohn's Disease and Ulcerative Colitis, official documents state Remicade is indicated for use in adult patients who have had an inadequate response to conventional therapy.

Q: Is it normal to feel tired or fatigued after a Remicade infusion?

A: Fatigue and tiredness are listed among the common adverse reactions reported by patients in clinical trials. Symptoms such as severe or extreme tiredness are listed as conditions that should be discussed with a healthcare professional.

Q: Do you get a fever after a Remicade infusion?

A: Fever is listed among the common adverse reactions reported in clinical trials. It is also documented as a symptom of an infusion reaction, which can occur during or soon after administration, or a sign of a serious infection.

Q: Are there any long-term side effects associated with Remicade?

A: The official label includes a Boxed Warning that highlights risks of serious infections (like the reactivation of Tuberculosis and Hepatitis B), and certain malignancies (such as lymphoma). These risks are documented as considerations within the official warnings and precautions section.

Q: Can Remicade be taken during pregnancy?

A: The official labeling states that Remicade is not recommended for use in pregnant women or breastfeeding mothers. Official guidance includes specific timing restrictions for live vaccines in infants who were exposed in utero.

Q: Is there an age limit for people who can receive Remicade?

A: Remicade is approved for use in pediatric patients 6 years of age and older for Crohn's Disease and Ulcerative Colitis. Regulatory documents state that the dose does not require adjustment for older adults (the geriatric population).

Q: Are there any food or drink restrictions while on Remicade?

A: Official documents do not report an interaction with food. However, the label contains a warning that because both Remicade and alcohol can affect the liver, consuming alcohol while on Remicade may increase the potential for liver damage.

Q: Can Remicade make you more susceptible to getting a cold or the flu?

A: Remicade functions as an immunosuppressant, which can lower your body's ability to fight infections. Common adverse reactions reported in clinical trials include respiratory tract infections such as sinusitis and pharyngitis, suggesting an increased potential for common infections.

Q: How long does it usually take before a person feels the effects of Remicade?

A: Clinical trial summaries indicate that symptomatic improvement for some patients can be observed shortly after treatment initiation. For example, some patients with Ankylosing Spondylitis saw improvement in signs and symptoms as early as 2 weeks after beginning treatment.

Q: What is the expected duration of treatment with Remicade?

A: Remicade is an established maintenance therapy intended to help control the chronic nature of inflammatory diseases. Clinical trials assess efficacy over long-term periods, such as up to two years, reflecting its role as a chronic treatment strategy.

Q: What percentage of people see improvement with Remicade based on studies?

A: The success rate varies by condition and time frame. For example, clinical trials for Ulcerative Colitis demonstrated that 61% to 69% of patients treated with Remicade had a clinical response at two months compared to placebo.

Q: Is Remicade generally considered a long-term treatment?

A: Yes, the general purpose of Remicade is to function as maintenance therapy for chronic inflammatory conditions. This function supports its use as a long-term strategy to help stabilize underlying disease activity.

Q: Is Remicade covered by insurance often?

A: Remicade is an originator biologic specialty medicine. Cost and coverage are dependent on the individual's commercial or private health insurance plan. Manufacturer savings programs are reported to be available for eligible patients with commercial or private insurance.

Q: How do doctors check if Remicade is working for a patient?

A: Clinical trials assess efficacy using endpoints such as the reduction in disease activity indices (e.g., CDAI in Crohn's) and the maintenance of clinical remission. Healthcare professionals monitor a patient’s response using clinical assessment and various diagnostic tests.

Q: Why do some people need a higher dose of Remicade than others?

A: Official dosing guidelines state that for adult patients who have had an inadequate therapeutic response to the standard dose, the dose may be increased up to a maximum of 10 mg/kg or the dosing interval may be shortened.

Q: Are there any reported interactions between Remicade and herbal supplements?

A: The official label advises patients to notify their healthcare professional of all concomitant medicines, including prescription and non-prescription medicines, vitamins, and herbal supplements.

Q: What kind of monitoring is necessary while on Remicade?

A: Patients are monitored for signs of serious infections, such as the reactivation of Tuberculosis and Hepatitis B. Additionally, patients with heart failure must receive close monitoring, and vital signs are checked during the infusion.

Q: Does Remicade have any effect on liver function?

A: The official regulatory label notes a risk of severe hepatotoxicity (liver injury) and the potential for reactivation of Hepatitis B Virus in carriers. Symptoms of liver injury, such as jaundice or fever, are listed as requiring immediate reporting.

How should Remicade be stored and disposed of?

How to Store and Dispose of Remicade

Official regulatory guidelines strictly define the storage and handling of Remicade (infliximab) to ensure product stability.

Storage Requirements

Unopened vials must be stored under refrigeration at 2 C to 8 C (36 F to 46 F). It is mandatory to store the vials in the original carton for protection from light and to not freeze the product. The product has a single exception allowing storage up to 30 C for a maximum of six months, but the vials cannot be returned to the refrigerator afterward. The medicine must be kept out of the reach of children.

Stability and Disposal

The final infusion must be initiated within 3 hours of preparation. Since the medicine is preservative-free, any unused portion of the reconstituted solution or final infusion must be discarded immediately. Disposal of unused product and waste must be performed according to local regulatory requirements.

Remicade